Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

FendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface Coating

FendX Pivots Manufacturing Strategy Amidst Partnership Exit

Executive Summary
  • FendX Technologies Inc. entered a Statement of Work (SOW) with Galenvs Sciences Inc. for pilot-scale manufacturing of its liquid surface coating.
  • The project involves producing three independent lots to evaluate antimicrobial performance, consistency, and manufacturability.
  • Simultaneously, the company terminated its Collaboration Agreement and Memorandum of Understanding with Aquaox LLC.
  • Reason for termination: The initial technical feasibility phase was deemed not feasible by FendX management.
  • A provisional patent was filed on October 21, 2025, for the liquid surface coating technology.
  • Management states this pilot is an important step toward commercialization with a potentially streamlined pathway to scale-up at low cost of manufacturing.
Material Impact
  • The news represents incremental progress on the flagship liquid surface coating product rather than a fundamental shift in business model or revenue generation.
  • Termination of the Aquaox agreement removes potential external validation and partnership upside, signaling execution risk in that specific collaboration avenue.
  • Engaging Galenvs confirms management is proceeding with internal manufacturing scale-up plans previously outlined in the March 31 corporate update.
  • The debt settlement announced earlier (April 10) reduced liabilities but increased share count, indicating continued reliance on equity dilution to manage cash flow.
  • Given the stock price decline from $1.00 in January to $0.37 in March, this news acts as a stabilization measure rather than a catalyst for significant re-rating without revenue proof.
FNDX · Price
Company Overview
  • FendX Technologies Inc. focuses on antimicrobial technologies for healthcare, consumer, and commercial markets.
  • Flagship Project: Liquid Surface Coating designed to provide sustained antimicrobial protection on high-touch surfaces using nanoparticle technology.
  • Secondary Projects: Foley catheter coating program and an AI-driven surface contamination detection app (both have provisional patents filed).
  • Development Stage: Pre-revenue; currently in pilot manufacturing and patent filing stages.
  • Previous Product Line: REPELWRAP film development was discontinued to focus on the liquid formulation.
Read the original news release →

More from FendX Technologies Inc.